Assertio (ASRT) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Assertio Revenue Highlights

Latest Revenue (Y)

$124.96M

Latest Revenue (Q)

$29.20M

Main Segment (Y)

Product

Main Geography (Y)

CANADA

Assertio Revenue by Period

Assertio Revenue by Year

Date	Revenue	Change
2024-12-31	$124.96M	-17.83%
2023-12-31	$152.07M	-2.67%
2022-12-31	$156.23M	40.73%
2021-12-31	$111.01M	4.46%
2020-12-31	$106.28M	-53.69%
2019-12-31	$229.50M	-26.39%
2018-12-31	$311.77M	-18.11%
2017-12-31	$380.72M	-16.49%
2016-12-31	$455.90M	33.02%
2015-12-31	$342.74M	-12.20%
2014-12-31	$390.36M	190.87%
2013-12-31	$134.21M	47.78%
2012-12-31	$90.82M	-31.70%
2011-12-31	$132.97M	64.64%
2010-12-31	$80.76M	39.90%
2009-12-31	$57.73M	65.69%
2008-12-31	$34.84M	-46.87%
2007-12-31	$65.58M	586.63%
2006-12-31	$9.55M	116.81%
2005-12-31	$4.41M	2074.73%
2004-12-31	$202.57K	-79.37%
2003-12-31	$981.99K	-40.89%
2002-12-31	$1.66M	-54.78%
2001-12-31	$3.67M	106.81%
2000-12-31	$1.78M	1440.16%
1999-12-31	$115.33K	-85.58%
1998-12-31	$800.00K	33.33%
1997-12-31	$600.00K	100.00%
1996-12-31	$300.00K	-

Assertio generated $124.96M in revenue during NA 2024, up -17.83% compared to the previous quarter, and up 54.45% compared to the same period a year ago.

Assertio Revenue by Quarter

Date	Revenue	Change
2024-09-30	$29.20M	-6.17%
2024-06-30	$31.13M	-4.07%
2024-03-31	$32.45M	-1.63%
2023-12-31	$32.98M	-7.42%
2023-09-30	$35.63M	-13.09%
2023-06-30	$40.99M	-3.47%
2023-03-31	$42.47M	-15.66%
2022-12-31	$50.35M	47.18%
2022-09-30	$34.21M	-2.62%
2022-06-30	$35.13M	-3.85%
2022-03-31	$36.54M	9.62%
2021-12-31	$33.33M	30.85%
2021-09-30	$25.47M	0.39%
2021-06-30	$25.37M	-5.46%
2021-03-31	$26.84M	-11.06%
2020-12-31	$30.18M	-12.70%
2020-09-30	$34.56M	67.65%
2020-06-30	$20.62M	-1.43%
2020-03-31	$20.92M	-64.68%
2019-12-31	$59.23M	7.40%
2019-09-30	$55.15M	-3.59%
2019-06-30	$57.20M	-1.25%
2019-03-31	$57.93M	35.99%
2018-12-31	$42.60M	-45.03%
2018-09-30	$77.49M	22.47%
2018-06-30	$63.27M	-50.72%
2018-03-31	$128.40M	36.01%
2017-12-31	$94.41M	-1.05%
2017-09-30	$95.41M	-5.02%
2017-06-30	$100.46M	11.07%
2017-03-31	$90.45M	-27.01%
2016-12-31	$123.91M	12.11%
2016-09-30	$110.52M	-5.28%
2016-06-30	$116.68M	11.36%
2016-03-31	$104.78M	-5.75%
2015-12-31	$111.17M	6.02%
2015-09-30	$104.86M	10.95%
2015-06-30	$94.50M	193.46%
2015-03-31	$32.20M	-83.45%
2014-12-31	$194.60M	277.98%
2014-09-30	$51.48M	-23.99%
2014-06-30	$67.73M	-11.51%
2014-03-31	$76.54M	88.49%
2013-12-31	$40.61M	8.41%
2013-09-30	$37.46M	25.02%
2013-06-30	$29.96M	14.48%
2013-03-31	$26.17M	-1.56%
2012-12-31	$26.59M	-20.11%
2012-09-30	$33.28M	135.88%
2012-06-30	$14.11M	-16.19%
2012-03-31	$16.84M	38.77%
2011-12-31	$12.13M	-26.57%
2011-09-30	$16.52M	-22.13%
2011-06-30	$21.22M	-74.47%
2011-03-31	$83.10M	298.39%
2010-12-31	$20.86M	3.64%
2010-09-30	$20.13M	-17.58%
2010-06-30	$24.42M	58.98%
2010-03-31	$15.36M	16.06%
2009-12-31	$13.23M	-42.50%
2009-09-30	$23.01M	98.26%
2009-06-30	$11.61M	17.59%
2009-03-31	$9.87M	13.28%
2008-12-31	$8.71M	-38.24%
2008-09-30	$14.11M	123.45%
2008-06-30	$6.32M	10.77%
2008-03-31	$5.70M	7.87%
2007-12-31	$5.29M	-

Assertio generated $29.20M in revenue during Q3 2024, up -6.17% compared to the previous quarter, and up 71.24% compared to the same period a year ago.

Assertio Revenue Breakdown

Assertio Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 22	Dec 21	Dec 20
Product and Service, Other	$2.10M	$-985.00K	$9.10M	-
Product	$120.85M	$155.12M	$109.42M	$93.50M
Product, Other	$1.52M	$4.67M	$5.03M	-
Royalties And Milestones	$2.01M	$2.40M	$2.58M	$1.52M
SPRIX Nasal Spray	$7.62M	$9.11M	$8.68M	$11.08M
CAMBIA	$5.56M	-	-	-
INDOCIN Products	$26.76M	$100.34M	$60.56M	$31.68M
Otrexup	$8.84M	$11.15M	-	-
Other Revenue	-	$-1.29M	$-985.00K	-
C A M B I A	-	$24.72M	$24.97M	$28.35M
Zipsor	-	$3.36M	$10.19M	$13.29M
Commercialization Agreement	-	-	-	$11.26M

Assertio's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (68.95%), INDOCIN Products (15.27%), Otrexup (5.04%), SPRIX Nasal Spray (4.35%), CAMBIA (3.17%), Product and Service, Other (1.20%), Royalties And Milestones (1.15%), and Product, Other (0.87%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Product, Other	$1.30M	$214.00K	$12.00K	$605.00K	$796.00K	$786.00K	$884.00K	$1.64M	$1.31M	-	-	-	-	-	-	-
Otrexup	$7.04M	$1.80M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
INDOCIN Products	$21.09M	$5.67M	$17.95M	$28.07M	$30.35M	$34.27M	$21.87M	$21.36M	$18.34M	$13.07M	$14.60M	$12.48M	$13.77M	$5.43M	-	-
CAMBIA	$4.19M	$1.36M	$1.99M	$1.80M	$2.26M	$5.81M	$5.47M	$6.13M	$6.46M	$7.45M	-	-	-	-	-	-
SPRIX Nasal Spray	$5.63M	$2.00M	$2.54M	$2.37M	$1.89M	$2.67M	$2.46M	$1.77M	$1.76M	$2.94M	$1.70M	$3.83M	$5.64M	$1.60M	-	-
Royalties And Milestones	$1.51M	$499.00K	$490.00K	$723.00K	$697.00K	$487.00K	$473.00K	$451.00K	$992.00K	$1.19M	$416.00K	$542.00K	$434.00K	$361.00K	$299.00K	$452.00K
Product	$92.14M	$28.70M	$35.14M	$40.08M	$41.77M	$49.86M	$34.28M	$35.43M	$35.55M	$32.15M	$26.00M	$24.83M	$26.41M	$29.82M	$34.27M	$20.16M
Product and Service, Other	-	-	-	$185.00K	$-540.00K	$-750.00K	-	$-9.00K	$-941.00K	$105.00K	$1.43M	$2.63M	$4.01M	-	-	-
Zipsor	-	-	$597.00K	$1.00M	$1.15M	$660.00K	$259.00K	$2.23M	$3.38M	$2.58M	$2.22M	$4.03M	$3.40M	$3.54M	-	-
Otrexup Acquisition	-	-	$2.81M	$3.59M	$2.82M	$3.00M	$3.08M	-	-	-	-	-	-	-	-	-
C A M B I A	-	-	-	-	-	$7.26M	$7.34M	$6.85M	$7.78M	-	-	-	-	-	-	-
Commercialization Agreement	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Commercialization Rights And Facilitation Services	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
OXAYDO	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$517.00K
Gralise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-116.00K
SOLUMATRIX Products	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$836.00K
Janssen Nucynta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$577.00K

Assertio's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (69.32%), INDOCIN Products (15.87%), Otrexup (5.30%), SPRIX Nasal Spray (4.23%), CAMBIA (3.15%), Royalties And Milestones (1.14%), and Product, Other (0.98%).

Assertio Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 22	Dec 21	Dec 20
CANADA	$2.00M	$1.90M	$2.50M	$1.50M

Assertio's latest annual revenue breakdown by geography, as of Dec 24: CANADA (100.00%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 20	Sep 20
CANADA	$1.50M	$500.00K	$500.00K	$400.00K	$500.00K	$400.00K	$500.00K	$500.00K	$500.00K	$300.00K	$300.00K

Assertio's latest quarterly revenue breakdown by geography, as of Dec 24: CANADA (100.00%).

Assertio Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RDY	Dr. Reddy's Laboratories	$279.16B	-
AMRX	Amneal Pharmaceuticals	$2.79B	$702.47M
NBIX	Neurocrine Biosciences	$2.36B	$622.10M
ALKS	Alkermes	$1.56B	$378.14M
AMPH	Amphastar Pharmaceuticals	$712.81M	$188.82M
PCRX	Pacira BioSciences	$700.97M	$168.57M
ITCI	Intra-Cellular Therapies	$680.85M	$175.38M
COLL	Collegium Pharmaceutical	$631.45M	$159.30M
ANIP	ANI Pharmaceuticals	$614.38M	$148.33M
IRWD	Ironwood Pharmaceuticals	$351.41M	$91.59M
ESPR	Esperion Therapeutics	$332.31M	$51.63M
EOLS	Evolus	$264.31M	$60.16M
LFCR	Lifecore Biomedical	$128.26M	$35.15M
ASRT	Assertio	$124.96M	$29.20M
ALVO	Alvotech	$91.43M	$12.43M

ASRT Revenue FAQ

What is Assertio’s yearly revenue?

Assertio's yearly revenue for 2024 was $124.96M, representing a decrease of -17.83% compared to 2023. The company's yearly revenue for 2023 was $152.07M, representing a decrease of -2.67% compared to 2022. ASRT's yearly revenue for 2022 was $156.23M, representing an increase of 40.73% compared to 2021.

What is Assertio’s quarterly revenue?

Assertio's quarterly revenue for Q3 2024 was $29.2M, a -6.17% decrease from the previous quarter (Q2 2024), and a -18.03% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $31.13M, a -4.07% decrease from the previous quarter (Q1 2024), and a -24.07% decrease year-over-year (Q2 2023). ASRT's quarterly revenue for Q1 2024 was $32.45M, a -1.63% decrease from the previous quarter (Q4 2023), and a -23.59% decrease year-over-year (Q1 2023).

What is Assertio’s revenue growth rate?

Assertio's revenue growth rate for the last 3 years (2022-2024) was -20.02%, and for the last 5 years (2020-2024) was 17.58%.

What are Assertio’s revenue streams?

Assertio's revenue streams in c 24 are Product and Service, Other, Product, Product, Other, Royalties And Milestones, SPRIX Nasal Spray, CAMBIA, INDOCIN Products, and Otrexup. Product and Service, Other generated $2.1M in revenue, accounting 1.20% of the company's total revenue, down -313.20% year-over-year. Product generated $120.85M in revenue, accounting 68.95% of the company's total revenue, down -22.09% year-over-year. Product, Other generated $1.52M in revenue, accounting 0.87% of the company's total revenue, down -67.49% year-over-year. Royalties And Milestones generated $2.01M in revenue, accounting 1.15% of the company's total revenue, down -16.27% year-over-year. SPRIX Nasal Spray generated $7.62M in revenue, accounting 4.35% of the company's total revenue, down -16.31% year-over-year. CAMBIA generated $5.56M in revenue, accounting 3.17% of the company's total revenue INDOCIN Products generated $26.76M in revenue, accounting 15.27% of the company's total revenue, down -73.33% year-over-year. Otrexup generated $8.84M in revenue, accounting 5.04% of the company's total revenue, down -20.69% year-over-year.

What is Assertio’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Assertio was Product. This segment made a revenue of $120.85M, representing 68.95% of the company's total revenue.